Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT) reported strong financial results for Q4 and full year 2023, with total revenue growing to $98.2 million in Q4 and $361.1 million for the year. The company achieved a 22% increase in total revenue, driven by growth in test volume and revenue from their Afirma and Decipher businesses. Veracyte also highlighted key business achievements, including the acquisition of C2i Genomics Inc. and an agreement with Illumina. Despite a net loss for Q4 2023, the company remains optimistic about future growth and expects positive cash flow for the third consecutive year.

Positive

• Veracyte reported a total revenue of $98.2 million in Q4 2023, a 22% increase from the same period in 2022.
• Total revenue for full year 2023 reached $361.1 million, marking a 22% growth compared to 2022.
• The company saw a 30% increase in testing revenue for 2023, driven by strong performance in Decipher and Afirma tests.
• Veracyte acquired C2i Genomics Inc. to enhance their Veracyte Diagnostics Platform and expand cancer care capabilities.
• An agreement with Illumina was signed to develop tests as in vitro diagnostics for global expansion.
• Despite a net loss in Q4 2023, the company expects positive cash flow for the third consecutive year.
• Veracyte's 2024 financial outlook includes maintaining revenue guidance of $394 million to $402 million.
• The company anticipates ending 2024 with $230 million to $234 million in cash, cash equivalents, and short-term investments.

Negative

• Operating expenses for full year 2023 increased by 46% compared to 2022, reaching $315.5 million.
• Net loss for the full year 2023 was $74.4 million, including impairment charges of $68.3 million.
• Biopharmaceutical and other revenue decreased by 43% in 2023 compared to 2022 due to spending constraints.
• An impairment charge of $32.0 million in Q4 2023 impacted the net loss for the quarter.
• Non-GAAP operating expenses grew by 20% in 2023, reaching $240.7 million.

Insights

Financial Analyst

Veracyte's fourth quarter revenue increase of 22% to $98.2 million and a full-year revenue jump of the same percentage to $361.1 million are significant indicators of the company's growth trajectory. The growth was primarily driven by their Afirma and Decipher tests, which are integral to their product line. The increase in test volume by 21% and 24% for the quarter and year, respectively, suggests a solid demand for their diagnostic products. However, the net loss reported, including a substantial $32.0 million impairment charge, raises concerns about the company's valuation of acquired assets and the sustainability of their growth. From an operational standpoint, the positive cash flow for the third consecutive year and an increase in cash provided by operating activities indicate strong financial discipline and operational efficiency.

Market Research Analyst

Veracyte's strategic partnerships, such as the agreement with Illumina to develop in vitro diagnostics, showcase the company's commitment to expanding its global footprint in the diagnostics market. This move aligns with the industry trend towards precision medicine and personalization of healthcare. However, the decrease in biopharmaceutical and other revenue by 43% year-over-year may be reflective of broader industry challenges, such as budget constraints and reduced project volumes. Investors should consider the potential impact of these industry-wide factors on Veracyte's future revenue streams from this segment.

Medical Research Analyst

The acquisition of C2i Genomics Inc. and the subsequent addition of whole-genome minimal residual disease (MRD) capabilities to Veracyte's portfolio is a noteworthy development. MRD testing is an emerging area in cancer care, offering the potential for early detection of relapse. Veracyte's ability to serve patients across the cancer care continuum could be significantly enhanced by this technology. Moreover, the clinical validation of the Percepta Nasal Swab test and the strengthening of the clinical-evidence library for Decipher Prostate with new publications are indicative of the company's focus on evidence-based products. These factors could contribute to long-term growth as they may lead to wider adoption of Veracyte's tests in clinical practice.

Grew Fourth Quarter Revenue to $98.2 million

Increased 2023 Total Revenue 22% to $361.1 million

Conference Call and Webcast Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.

“We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses,” said Marc Stapley, Veracyte’s chief executive officer. “Looking to 2024 and beyond, we will leverage our Veracyte Diagnostics Platform to continue to drive near- and long-term revenue. With multiple growth catalysts over the coming years and with our strong financial discipline, we expect to achieve positive cash flow for the third consecutive year and going forward.”

Key Business Highlights

• Grew total test volume to 33,836 in the fourth quarter and 126,977 for the full year 2023, an increase of 21% and 24%, respectively, compared to the prior year periods.
• Enhanced our Endocrinology offering in 2023 with the launch of TERT promoter mutation testing for Afirma, the introduction of our Afirma GRID research tool, and enhancements to our online physician ordering portal.
• Continued to strengthen the body of evidence for Decipher Prostate in 2023, adding 8 publications and 16 abstracts to the clinical-evidence library, reinforcing Decipher’s status as the only molecular test to receive Level 1 evidence designation in the National Comprehensive Cancer Network’s (NCCN) prostate cancer guidelines.
• Acquired C2i Genomics Inc., adding whole-genome minimal residual disease (MRD) capabilities to our novel Veracyte Diagnostics Platform and expanding our ability to serve patients across the cancer care continuum.
• Signed an agreement with Illumina to develop some of our tests as in vitro diagnostics (IVDs) for use on their NextSeq 550Dx next-generation sequencing (NGS) instrument, as part of our multi-platform strategy to accelerate global expansion of our tests as IVDs.
• Published the clinical validation study for our Percepta Nasal Swab test in CHEST.
• For the full year, generated $44 million of cash from operations and ended the year with $216 million of cash and cash equivalents.

Fourth Quarter 2023 Financial Results

Total revenue for the fourth quarter of 2023 was $98.2 million, an increase of 22% compared to $80.3 million reported in the fourth quarter of 2022. Testing revenue was $90.4 million, an increase of 29% compared to $70.3 million in the fourth quarter of 2022, driven primarily by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $3.7 million, an increase of 13% compared to $3.2 million in the fourth quarter of 2022. Biopharmaceutical and other revenue was $4.1 million, a decrease of 39% compared to $6.8 million in the fourth quarter of 2022.

Total gross margin for the fourth quarter of 2023, including the amortization of acquired intangible assets, was 66%, compared to 61% in the fourth quarter of 2022. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 70%, compared to 67% in the fourth quarter of 2022.

Operating expenses, excluding cost of revenue, were $100.3 million, which included an impairment charge of $32.0 million associated with the impairment of HalioDx developed biopharmaceutical services technology, customer relationships and customer backlog finite-lived intangible assets, compared to $54.1 million in the fourth quarter of 2022. Non-GAAP operating expenses, which excludes cost of revenue, amortization of acquired intangible assets, impairment charges, other acquisition related expenses, and other restructuring costs, grew 28% to $65.6 million, including a technology access fee of $3.5 million to develop our IVD kitted tests on an NGS platform, compared to $51.1 million in the fourth quarter of 2022.

Net loss for the fourth quarter of 2023 was $28.3 million, and basic and diluted net loss per common share was $0.39, which includes the aforementioned $32.0 million impairment charge. Net cash provided by operating activities in the fourth quarter of 2023 was $15.6 million, an improvement of $5.8 million compared to the same period in 2022.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading “Note Regarding Use of Non-GAAP Financial Measures.”

Full Year 2023 Financial Results

Total revenue for 2023 was $361.1 million, an increase of 22% compared to $296.5 million in 2022. Testing revenue was $326.5 million, an increase of 30% compared to $250.5 million in 2022, driven primarily by the strong performance of our Decipher and Afirma tests. Product revenue was $15.6 million, an increase of 23% compared to $12.6 million in 2022. Biopharmaceutical and other revenue was $18.9 million, a decrease of 43% compared to $33.4 million in 2022, driven by the reduction of customer projects given overall spending constraints across the industry.

Total gross margin for the full year 2023, including the amortization of acquired intangible assets, was 64%, compared to 59% in 2022. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 69%, compared to 66% in 2022.

Operating expenses, excluding cost of revenue, were $315.5 million, an increase of 46% compared to $216.8 million in 2022. Non-GAAP operating expenses, which excludes cost of revenue, amortization of acquired intangible assets, impairment charges, other acquisition related expenses and other restructuring costs, grew 20% to $240.7 million compared to $200.3 million in 2022.

Net loss for the full year 2023 was $74.4 million and basic and diluted net loss per common share was $1.02, which includes impairment charges of $68.3 million in the year. Net cash provided by operating activities in 2023 was $44.2 million, an increase of $36.7 million compared to 2022.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

2024 Financial Outlook

The company is maintaining full-year 2024 total revenue guidance of $394 million to $402 million and, consistent with prior guidance, expects cash, cash equivalents and short-term investments at the end of the year to be $230 million to $234 million.

Conference Call and Webcast Details

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/tkiac6t9. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-in can be accessed by registering at the following link: https://register.vevent.com/register/BI38de228ea0a04e0ab786cfe56be5ca1b

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to 2024 financial and operating results; statements regarding the expected benefits of the acquisition of C2i Genomics; and our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration the business and realize expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies and energy supply, as well as our facilities in France; the impact of foreign currency fluctuations, increasing interest rates, inflation, potential government shutdowns and turmoil in the global banking and finance system; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended September 30, 2023, filed on November 8, 2023, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, Decipher, C2i Genomics, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

Note Regarding Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non‐GAAP results including non-GAAP gross margin, non-GAAP operating expenses, and non-GAAP loss from operations. These measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP measures we present may be different from those used by other companies.

We exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related HalioDx intangible assets and certain costs related to restructuring from certain of our non-GAAP measures. Management has excluded the effects of these items in non-GAAP measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business.

Reconciliations between our GAAP results and non‐GAAP financial measures are presented in the tables of this release.

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
	Three Months Ended December 31								Twelve Months Ended December 31
		2023				2022				2023				2022
Revenues:
Testing revenue	$	90,385			$	70,269			$	326,542			$	250,544
Product revenue		3,665				3,231				15,588				12,632
Biopharmaceutical and other revenue		4,149				6,797				18,921				33,360
Total revenue		98,199				80,297				361,051				296,536
Operating expenses (1):
Cost of testing revenue		24,105				19,394				88,913				75,317
Cost of product revenue		1,753				2,618				8,666				7,820
Cost of biopharmaceutical and other revenue		3,518				4,819				15,324				18,445
Research and development		18,673				11,287				57,305				40,603
Selling and marketing		25,260				24,127				101,490				97,560
General and administrative		23,795				18,208				86,229				73,200
Impairment of long-lived assets		32,039				—				68,349				3,318
Intangible asset amortization		4,563				5,264				20,570				21,354
Total operating expenses		133,706				85,717				446,846				337,617
Loss from operations		(35,507	)			(5,420	)			(85,795	)			(41,081	)
Other income, net		5,035				1,979				9,183				4,654
Loss before income taxes		(30,472	)			(3,441	)			(76,612	)			(36,427	)
Income tax (benefit) provision		(2,179	)			403				(2,208	)			133
Net loss	$	(28,293	)		$	(3,844	)		$	(74,404	)		$	(36,560	)
Net loss per common share, basic and diluted	$	(0.39	)		$	(0.05	)		$	(1.02	)		$	(0.51	)
Shares used to compute net loss per common share, basic and diluted		73,107,059				71,825,754				72,644,487				71,549,204

1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:
	Three Months Ended December 31						Twelve Months Ended December 31
	2023			2022			2023			2022
Cost of revenue	$	472		$	408		$	1,858		$	1,355
Research and development		1,495			1,332			5,326			6,132
Selling and marketing		2,498			1,297			9,624			6,018
General and administrative		3,142			3,997			16,681			13,951
Total stock-based compensation expense	$	7,607		$	7,034		$	33,489		$	27,456

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS
(Unaudited)
(In thousands)
	Three Months Ended December 31								Twelve Months Ended December 31
		2023				2022				2023				2022
Net loss	$	(28,293	)		$	(3,844	)		$	(74,404	)		$	(36,560	)
Other comprehensive income (loss):
Change in currency translation adjustments		3,765				22,720				7,328				(16,263	)
Net comprehensive loss	$	(24,528	)		$	18,876			$	(67,076	)		$	(52,823	)

VERACYTE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	December 31,			December 31,
	2023			2022
	(Unaudited)			(See Note 1)
Assets
Current assets:
Cash and cash equivalents	$	216,454		$	154,247
Short-term investments		—			24,605
Accounts receivable		40,378			44,021
Supplies and inventory		16,128			14,294
Prepaid expenses and other current assets		12,661			11,469
Total current assets		285,621			248,636
Property, plant and equipment, net		20,584			17,702
Right-of-use assets, operating leases		10,277			13,160
Intangible assets, net		88,593			174,866
Goodwill		702,984			695,891
Restricted cash		876			749
Other assets		5,971			5,418
Total assets	$	1,114,906		$	1,156,422
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	12,943		$	11,911
Accrued liabilities		38,427			37,774
Current portion of deferred revenue		2,008			2,613
Current portion of acquisition-related contingent consideration		2,657			6,060
Current portion of operating lease liabilities		5,105			4,070
Current portion of other liabilities		101			186
Total current liabilities		61,241			62,614
Deferred tax liabilities		734			4,531
Acquisition-related contingent consideration, net of current portion		518			2,498
Operating lease liabilities, net of current portion		7,525			10,648
Other liabilities		786			931
Total liabilities		70,804			81,222
Total stockholders’ equity		1,044,102			1,075,200
Total liabilities and stockholders’ equity	$	1,114,906		$	1,156,422
1. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated March 1, 2023.

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
	Twelve Months Ended December 31
		2023				2022
Operating activities
Net loss	$	(74,404	)		$	(36,560	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		27,188				25,928
Loss on disposal of property and equipment		271				206
Stock-based compensation		33,141				26,734
Deferred income taxes		(3,839	)			133
Interest on end-of-term debt obligation		—				161
Noncash lease expense		4,158				3,320
Revaluation of acquisition-related contingent consideration		(5,383	)			154
Impairment loss		68,349				3,318
Effect of foreign currency on operations		(1,096	)			522
Changes in operating assets and liabilities:
Accounts receivable		3,887				(4,495	)
Supplies and inventory		(1,694	)			(3,011	)
Prepaid expenses and other current assets		(458	)			1,390
Other assets		(758	)			(3,049	)
Operating lease liability		(4,330	)			(3,448	)
Accounts payable		(134	)			152
Accrued liabilities and deferred revenue		(676	)			(3,920	)
Net cash provided by operating activities		44,222				7,535
Investing activities
Purchase of short-term investments		(19,700	)			(33,519	)
Proceeds from sale of short-term investments		39,773				—
Proceeds from maturity of short-term investments		5,000				12,681
Purchases of property, plant and equipment		(9,961	)			(8,549	)
Net cash provided by (used in) investing activities		15,112				(29,387	)
Financing activities
Payment of long-term debt		—				(1,281	)
Payment of taxes on vested restricted stock units		(6,741	)			(3,167	)
Proceeds from the exercise of common stock options and employee stock purchases		9,578				7,942
Net cash provided by financing activities		2,837				3,494
Increase (decrease) in cash, cash equivalents and restricted cash		62,171				(18,358	)
Effect of foreign currency on cash, cash equivalents and restricted cash		163				(592	)
Net increase (decrease) in cash, cash equivalents and restricted cash		62,334				(18,950	)
Cash, cash equivalents and restricted cash at beginning of year		154,996				173,946
Cash, cash equivalents and restricted cash at end of period	$	217,330			$	154,996

CASH, CASH EQUIVALENTS AND RESTRICTED CASH
(Unaudited)
(In thousands)
	December 31,			December 31,
	2023			2022
Cash and cash equivalents	$	216,454		$	154,247
Restricted cash		876			749
Total cash, cash equivalents and restricted cash	$	217,330		$	154,996

Reconciliation of U.S. GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands)
					Identified Expenses
	GAAP				Acquisition Related Expenses (1)			Intangible Assets Amortization Expense			Other (4)			Total Non-GAAP Measure
Three Months Ended December 31, 2023
Total revenue	$	98,199			$	—		$	—		$	—		$	98,199
Cost of testing revenue		24,105				—			—			—			24,105
Cost of product revenue		1,753				—			—			—			1,753
Cost of biopharmaceutical and other revenue		3,518				—			—			—			3,518
Intangible asset amortization (2)		4,035				—			4,035			—			—
Gross margin $		64,788				—			4,035			—			68,823
Gross margin %		66	%												70	%
Research and development		18,673				—			—			—			18,673
Selling and marketing		25,260				294			—			—			24,966
General and administrative		23,795				1,867			—			—			21,928
Impairment of long-lived assets		32,039				—			—			32,039			—
Intangible asset amortization		528				—			528			—			—
Total operating expenses excluding cost of revenue (3)		100,295				2,161			528			32,039			65,567
Income (loss) from operations	$	(35,507	)		$	2,161		$	4,563		$	32,039		$	3,256
Three Months Ended December 31, 2022
Total revenue	$	80,297			$	—		$	—		$	—		$	80,297
Cost of testing revenue		19,394				50			—			—			19,344
Cost of product revenue		2,618				—			—			—			2,618
Cost of biopharmaceutical and other revenue		4,819				64			—			—			4,755
Intangible asset amortization (2)		4,747				—			4,747			—			—
Gross margin $		48,719				114			4,747			—			53,580
Gross margin %		61	%												67	%
Research and development		11,287				232			—			—			11,055
Selling and marketing		24,127				917			—			—			23,210
General and administrative		18,208				1,368			—			—			16,840
Impairment of long-lived assets		—				—			—			—			—
Intangible asset amortization		517				—			517			—			—
Total operating expenses excluding cost of revenue (3)		54,139				2,517			517			—			51,105
Income (loss) from operations	$	(5,420	)		$	2,631		$	5,264		$	—		$	2,475
1. Includes transaction related expenses as well as post-combination compensation expenses. For each of the three months ended December 31, 2022, and December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx. For the three months ended December 31, 2023 adjustments include the transaction related expenses associated with the acquisition of C2i Genomics.
2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.
3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue ($29.4 million and $26.8 million) and the amortization of intangible assets which would have been allocated to the cost of revenue ($4.0 million and $4.7 million) for the three months ended December 31, 2023 and for the three months ended December 31, 2022 respectively.
4. For the three months ended December 31, 2023, includes $32.0 million expense related to the impairment charge associated with HalioDx developed technology, customer relationships and customer backlog finite-lived intangible assets.
Reconciliation of U.S. GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands)
					Identified Expenses
	GAAP				Acquisition Related Expenses (1)			Intangible Assets Amortization Expense			Other (4)			Total Non-GAAP Measure
Twelve Months Ended December 31, 2023
Total revenue	$	361,051			$	—		$	—		$	—		$	361,051
Cost of testing revenue		88,913				83			—			—			88,830
Cost of product revenue		8,666				—			—			—			8,666
Cost of biopharmaceutical and other revenue		15,324				94			—			—			15,230
Intangible asset amortization (2)		18,464				—			18,464			—			—
Gross margin $		229,684				177			18,464			—			248,325
Gross margin %		64	%												69	%
Research and development		57,305				58			—			—			57,247
Selling and marketing		101,490				2,610			—			—			98,880
General and administrative		86,229				329			—			1,371			84,529
Impairment of long-lived assets		68,349				—			—			68,349			—
Intangible asset amortization		2,106				—			2,106			—			—
Total operating expenses excluding cost of revenue (3)		315,479				2,997			2,106			69,720			240,656
Income (loss) from operations	$	(85,795	)		$	3,174		$	20,570		$	69,720		$	7,669
Twelve Months Ended December 31, 2022
Total revenue	$	296,536			$	—		$	—		$	—		$	296,536
Cost of testing revenue		75,317				203			—			18			75,096
Cost of product revenue		7,820				—			—			3			7,817
Cost of biopharmaceutical and other revenue		18,445				325			—			—			18,120
Intangible asset amortization (2)		19,273				—			19,273			—			—
Gross margin $		175,681				528			19,273			21			195,503
Gross margin %		59	%												66	%
Research and development		40,603				1,418			—			—			39,185
Selling and marketing		97,560				3,914			—			493			93,153
General and administrative		73,200				5,245			—			—			67,955
Impairment of long-lived assets		3,318				—			—			3,318			—
Intangible asset amortization		2,081				—			2,081			—			—
Total operating expenses excluding cost of revenue (3)		216,762				10,577			2,081			3,811			200,293
Loss from operations	$	(41,081	)		$	11,105		$	21,354		$	3,832		$	(4,790	)
1. Includes transaction related expenses as well as post-combination compensation expenses, adjustments consist primarily remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HalioDx and transaction related expenses associated with the acquisition of C2i Genomics.
2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.
3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue ($112.9 and $101.6 million) and the amortization of intangible assets which would have been allocated to the cost of revenue ($18.5 and $19.3 million) for the full year 2023 and 2022 respectively.
4. 2022 includes $3.3 million expense related to the impairment charge associated with certain developed technology intangible assets; 2023 includes $34.9 million expense related to the impairment charge associated with the nCounter license intangible assets, $32.0 million related to the impairment charge associated with HalioDx developed technology, customer relationships and customer backlog finite-lived intangible assets, $1.4 million related to the departure of the former executive chair and $1.4 million related to restructuring costs.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222312513/en/

Investor Contact:

Shayla Gorman

investors@veracyte.com

619-393-1545

Media Contact:

Tracy Morris

media@veracyte.com

650-380-4413

Source: Veracyte, Inc.

FAQ

What was Veracyte's total revenue for Q4 2023?

Veracyte reported a total revenue of $98.2 million in Q4 2023, a 22% increase from the same period in 2022.

What was the total revenue for Veracyte in 2023?

Total revenue for full year 2023 reached $361.1 million, marking a 22% growth compared to 2022.

What was the increase in testing revenue for Veracyte in 2023?

The company saw a 30% increase in testing revenue for 2023, driven by strong performance in Decipher and Afirma tests.

What acquisitions did Veracyte make in 2023?

Veracyte acquired C2i Genomics Inc. to enhance their Veracyte Diagnostics Platform and expand cancer care capabilities.

What agreement did Veracyte sign in 2023?

An agreement with Illumina was signed to develop tests as in vitro diagnostics for global expansion.

What is Veracyte's financial outlook for 2024?

Veracyte's 2024 financial outlook includes maintaining revenue guidance of $394 million to $402 million.

What is Veracyte's cash position expectation for the end of 2024?

The company anticipates ending 2024 with $230 million to $234 million in cash, cash equivalents, and short-term investments.